Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart pacemaker tweak aimed at easing chest pain and fatigue – but study stopped early

NCT ID NCT06775886

Symptom relief Sponsor: Montefiore Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether a personalized pacing algorithm (myPACE+) could improve quality of life and exercise capacity in people with non-obstructive hypertrophic cardiomyopathy who already have an implantable defibrillator. Only one person was enrolled before the trial was terminated, so no meaningful results were obtained. The idea was to see if tailored pacing could reduce symptoms like shortness of breath and fatigue.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
myPACE+ algorithm (personalized accelerated pacing via implanted ICD)
What this could lead to
If it worked, this could offer a non-drug way to ease symptoms and improve daily life for people with this type of heart condition.
What could go wrong
The trial was terminated after enrolling only 1 participant, so no reliable conclusions can be drawn. The approach is experimental and unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

1 person

The number who actually took part.

Started

Oct 2025

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Non obstructive HCM: Left Ventricular Outflow Tract (LVOT) gradient \<30mmHg at rest and with provocation * Left ventricular ejection fraction (LVEF) ≥50% * New York Heart Association (NYHA II-III) symptoms * Normal intrinsic conduction system * Suitable dual-chamber implantable cardioverter defibrillators (ICD) system Exclusion Criteria: * Pregnancy * LVEF \<50% * LVOT gradient \> 30mmHg at rest or with provocation * Prolonged PR \> 250ms * Baseline RV-pacing burden of \> 1% more than moderate valvular stenosis or regurgitation * Aortic valve replacement in the past one year * Significant primary pulmonary disease on home oxygen * Uncontrolled hypertension as defined by BP \>160/100 mmHg on two measurements ≥15 minutes apart

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypertrophic cardiomyopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiomyopathy hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypertrophic cardiomyopathy Non-obstructive hypertrophic cardiomyopathy

Contacts and locations

Locations

  • Montefiore Medical Center

    The Bronx, New York, 10467, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.